Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity

Abstract

<i>ALK</i> resistance mutations increase with each successive generation of ALK TKI and may be underestimated by tumor genotyping. Sequential treatment with increasingly potent ALK TKIs may promote acquisition of <i>ALK</i> resistance mutations leading to treatment-refractory compound <i>ALK</i> mutations.